Study Group: Urologists who Perform Procedures Using the Da Vinci Surgical System(?)
Council Members in this Study Group: 67
Request a survey with this Study Group
Leading Experts in this Study Group
Attending Physician
Tri-County Urology
Mitchell Bamberger, MD, MBA, FACS, is an Associate Professor of Surgery at the University of Massachusetts Medical School in Worcester and an Attending Physician at TriCounty Urology Associates and Milford Regional Medical Center. Previously, Dr. Bamberger was the Chief of Urology at Saint Vincent Hospital,...
Ravi Munver, MDVice Chairman, Chief of Minimally Invasive Surgery
Hackensack University Medical Center
Ravi Munver, MD, is Vice Chairman and Chief of Minimally Invasive and Robotic Urologic Surgery at Hackensack University Medical Center, New Jersey. He is an Associate Professor of Urology and holds faculty appointments at Touro University College of Medicine and UMDNJ Medical School. Dr. Munver has...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The data gives a mixed review regarding the robotic assisted radical prostatectomy for prostate cancer. There is a clear advantage in regards to a significantly decreased risk of bleeding, post operative pain, and earlier return to normal activities. However, the data does not show a clinical...
Novel therapy for advance recurrent prostate cancer that does not rely upon traditional standard hormone therapy. This has the potential for men to continue to be sexually active while receiving treatment for advanced disease. It also opens the door to other therapeutic interventions.
The FDA has made the nasal spray formulation of DDAVP be withdrawn due to potential significant side effects of life threatening hyponatremia (low blood sodium) as well as potential seizures. I an unable to identify the data from this announcement as to why this occured. DDAVP nasal spray has been used...
This immunotherapy is based upon Insulin-like growth factor which may be expressed in prostate cancer. There is not much data on this. The study is very limited, 30 patients, and must not have received any chemotherapy prior to enrolling. The sponsor is IM Clone. I do not know...
The FDA recently approved Indevus' newest agent, Sanctura XR for the treatment of Overactive Bladder (OAB). Sanctura XR is a once daily formulation of its earlier drug, Sanctura. This is an important step since for Indevus if it wishes to remain competitive in the OAB market which is otherwise dominated...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Physician - Department Chair
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms